The Alluminox™ platform combines drugs with localized light to selectively destroy cancer and immunosuppressive cells while sparing healthy tissue. Pre-clinical studies suggest it may also activate the immune system for lasting anti-tumor effects, positioning it as a potential precision, immune-activating surgical approach. Real-world data from Japan shows a manageable safety profile and strong efficacy, with an overall response rate over 68% and complete response rates exceeding 30% in head and neck cancer and 73% in nasopharyngeal cancer.
We at ABIES Capital are honored to participate in this year's most significant pharmaceutical licensing and signing dinner between Japan and Taiwan. Mickey Mikitani, CEO of Rakuten Medical, stated that this partnership expands RMI's impact in Asia through the Alluminox™ platform. The global RMI team continues to advance the scientific foundation and clinical application of their therapy. He expressed his enthusiasm for working with OEP and Cyntec to bring this treatment to patients in Taiwan, Malaysia, Singapore, and the Philippines.
【新聞發佈】樂天醫藥與友華集團簽署獨家授權協議 推動 Alluminox™ 光免疫療法於台灣、馬來西亞、新加坡及菲律賓之共同開發與商業化
(Photo with CEO Mickey Mikitani, President Minami Maeda, and Rakuten Medical Taiwan Managing Director Louise Chang)